Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pyxis Oncology (PYXS) Accumulated Expenses (2024 - 2025)

Pyxis Oncology (PYXS) has disclosed Accumulated Expenses for 2 consecutive years, with $8.0 million as the latest value for Q3 2025.

  • On a quarterly basis, Accumulated Expenses fell 43.12% to $8.0 million in Q3 2025 year-over-year; TTM through Sep 2025 was $8.0 million, a 43.12% decrease, with the full-year FY2024 number at $11.4 million, changed N/A from a year prior.
  • Accumulated Expenses was $8.0 million for Q3 2025 at Pyxis Oncology, up from $6.7 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $14.1 million in Q3 2024 to a low of $6.7 million in Q2 2025.